Bone Biologics Corp
NASDAQ:BBLG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bone Biologics Corp
Cost of Revenue
Bone Biologics Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bone Biologics Corp
NASDAQ:BBLG
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$17.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.7B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.9B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-17%
|
|
Bone Biologics Corp
Glance View
Bone Biologics Corp. operates as a medical device company, which engages in the research and development of bone regeneration in spinal fusion. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is also focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX medical device is a combination product which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The NELL-1/DBX Fusion Device offers a range of procedures including Spine Implants, Non-Union Trauma Cases and Osteoporosis. NELL-1 is a function specific recombinant human protein in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.
